Update shared on 17 Nov 2025
Fair value Increased 0.084%Analyst Price Target Update for IHH Healthcare Berhad
Analysts have raised their price target for IHH Healthcare Berhad slightly from RM8.52 to RM8.53, citing small upward adjustments in profit margin forecasts. This comes despite marginally lower expectations for revenue growth and future price-to-earnings ratios.
What's in the News
- IHH Healthcare Berhad announced an interim single tier cash dividend of RMB 0.050 per ordinary share for the financial year ending 31 December 2025 (Key Developments).
- The ex-date for the dividend is set for 29 September 2025. The entitlement date is 30 September 2025 (Key Developments).
- Payment of the announced dividend is scheduled for 30 October 2025 (Key Developments).
Valuation Changes
- Fair Value has increased slightly from MYR 8.52 to MYR 8.53.
- Discount Rate has risen marginally from 8.45% to 8.49%.
- Revenue Growth projections have declined modestly from 8.98% to 8.96%.
- Net Profit Margin forecasts have improved slightly from 8.27% to 8.33%.
- Future P/E ratio expectations have decreased from 36.36x to 36.10x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.